Organovo Reaches Research Agreement with Merck

Yesterday it was announced that 3D Bioprinting company, Organovo had signed a multi-year research agreement with one of the world's largest drug companies, Merck. As a part of the agreement, Merck will gain access to Organovo's exVive3D line of printed human tissue, while Organovo will benefit from a collaborative research setup. The financial terms of the deal have not been announced, but the market certainly liked the news as shares of Organovo climbed 15% yesterday. More details on this deal can be found here: http://3dprint.com/60245/organovo-merck-3d-print/

http://3dprint.com/wp-content/uploads/2015/04/o41.png